But he gave no details in terms of calendar

Transgene does need new partners or funding to support clinical trials of its future four great therapeutic vaccines, whose commercial launch could be held in 2016, said its Director General Philippe Archinard, Reuters of biotechnology forum.

Transgene, specialist of therapeutic vaccines, has the goal of becoming a "pérennement profitable term" biopharmaceutical company, he said. But he gave no details in terms of calendar.

While in 2010 it provided to be beneficial in 2015, the company pushed the date of its first profits in an announcement in March, a loss of EUR 34.2 million in the year 2010, which was a loss of 27 million in 2009 and $ 18 million in 2008.

Transgene technology is immunotherapy: this is cause by the injection of genes in the body, the immune response to antibodies to fight foreign bodies, namely the cancer cells.

"Our priority is to ensure the proper implementation of clinical trials." "Once that it was made, it will be realized 99 of the course of creating value", said Philippe Archinard. "Today, it is rather on horizons of commercial launches in 2016."

A business strategy of vertical integration as a Transgene, profitability is slower if the marketing of a product is assigned to a partner who pays royalties on sales and supports the costs of marketing, he added.

NO DATE FOR THE FIRST PROFITS

Steps at this product, it is very difficult to say when Transgene will be

"If our products are consistent with the results they have obtained previously, is what need us in financial terms, in terms of partnership and in terms of competence to be successful our strategy", sued Philippe Archinard.

And added: "there are four projects, you will reach our goal if only one of its four projects successfully." "If there are four who walk, it will be exploded our goal."

On the four molecules in clinical development, two of which are potential blockbusters: the TG4010 (non-small cell lung cancer) which results from phase IIb are expected end 2012 - early 2013, and JX594/TG6006 (hepatocellular carcinoma) including the results of phase IIb are expected at the end of 2012.

Novartis has a license for the first option and the American Jennerex awarded to Transgene for exclusive rights for the development and commercialization in Europe, the CIS and the Middle East.

For these two products, Transgene has the intention to file his first application for the placing on the market by 2015.

Two other major projects of Transgene are the TG4040 (hepatitis C) which the company must determine here end 2012 if it launches phase III, and TG4001 (therapeutic vaccine against cervical cancer) which results from phase IIb are expected late 2011 - early 2012, and for which the Swiss Roche put an end to a license agreement.

CHINA FOCUS ONLINE

"For the TG4040 and TG 4001 will need a regional partner, but it is very tactical;" If you have success with our two most important products, it can take more risks and keep more rights on our other products in the contrary case. "History is not 100 written", said Philippe Archinard.

For example, he confirmed that Transgene intended to speed up its presence in China after the joint venture agreement concluded in 2010 with Tianjin Tasly Pharmaceuticals for the development and commercialization in the country of immunotherapy products.

"We must finalize this summer or in early December our local development plan and define products." "In parallel, we have a number of upstream research activities in Oncology and in the field of hepatitis, forms of highly recurrent diseases in China", he said.

Transgene will not be able to register products in China "before 5-6 years at best", he said, adding that "financially, there is very little of cash burn associated developments".

In addition to rock, the major actors in Oncology are GlaxoSmithKline, Sanofi, Merck, Eli Lilly or even Pfizer.

Institut Mérieux is owner of 55.2 of the capital of Transgene, founded in 1979 and introduced on the stock exchange in 1998.

The Transgene title deals at about 12.50 euros Tuesday, highlighting a market capitalization of approximately 397 million. He lost about 10 since the beginning of the year, after a drop of 32.6 last year.